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Abstract  
Purpose 
Delaying progression, ameliorating symptoms and maintaining Quality of Life (QoL) are 
primary aims of treatment for metastatic Castrate Resistant Prostate Cancer (mCRPC). Real 
world rather than clinical trial data about symptoms and side effects are sparse. In 
EXTREQOL patients’ QoL, pain and information needs were recorded during treatment. 
Methods 
Men with mCRPC from 20 UK cancer centres commencing various systemic mCRPC 
treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 
months. 
Results 
132 patients were recruited. Overall QoL declined significantly by 6 months (Functional 
Assessment of Cancer Therapy-Prostate (FACT-P) mean=-3.89, 95% CI: -6.7 to -1.05, p 
=0.007; Trial Outcome Index analysis (TOI) mean=-3.10, 95% CI: -5.34 to -0.83, p = 0.007. 
Those who came off novel therapy and remained on LHRH agonist therapy alone had worse 
scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale 
(PSC) mean difference= -4.45, 95% CI: 95% CI: -7.06 to -1.83, p-value=0.001; TOI mean 
difference = -5.62, 95% CI: -10.97 to -0.26, p =0.040).  At 3 & 6 months men who reported 
pain at baseline improved (43%; 40% respectively), but for others pain levels remained the 
same (45%; 42%) or worsened (13%; 18%). Information regarding supportive care was 
lacking throughout the period of time on the study. 
Conclusion 
Most mCRPC treated patients experience reduced QoL and inadequate pain control. More 
help with pain management and better information provision regarding supportive care is 
warranted.  
 
Keywords 
mCRPC; pain control; QoL; information needs; side effects 
 
 
 
 
Short Title: EXTREQOL study results revision 
2 
 
 
Introduction 
Prostate cancer is the most common cancer in UK men [1]. Over the course of the illness 
many will face multiple treatment options, dependent on the stage of cancer at the time of 
their diagnosis. Surgical and radiotherapy techniques have improved, and there are more 
drugs available offering prospects for an extended life of good quality. Unfortunately, for the 
majority of men presenting with or progressing to advanced (metastatic prostate) disease, 
the development of metastatic castrate resistant prostate cancer (mCRPC) is inevitable.  
Docetaxel chemotherapy became the standard of care for mCPRC patients with good 
performance status a decade ago following the results of the TAX 327 study [2], and many 
men remain fit enough to receive further systemic therapy on progression after docetaxel. 
Cabazitaxel chemotherapy was licensed in Europe in 2011 for use in mCRPC after 
docetaxel following results of the TROPIC trial [3]. As well as advances in chemotherapy, 
other treatments have become available including the novel hormone agents, abiraterone 
acetate (androgen biosynthesis inhibitor), and enzalutamide (androgen receptor antagonist). 
These compounds have demonstrated significant survival benefits for patients in Phase III 
clinical trials in the docetaxel naïve setting and also in men who have progressed after 
chemotherapy [4-6]. In addition, other agents such as radium-223 [7] have also shown 
improvements in overall survival; the immunotherapies and other agents are under 
investigation. 
The main aims of treatment for mCRPC are to delay progression, ameliorate symptoms and 
maintain or improve quality of survival. From a patient’s perspective, optimal treatment is a 
trade-off between efficacy and tolerability, and while the increasing number of therapeutic 
options is welcome, a review of mCRPC clinical trial publications noted that Patient Reported 
Outcomes (PROs) were either not measured routinely or failed to be reported adequately 
hampering evaluation [8]. Those with good PRO data showed that enzalutamide compared 
with placebo significantly improved Quality of Life (QoL) in the AFFIRM trial [9], and in the 
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PREVAIL trial was associated with a reduced risk of and delayed time to QoL deterioration, 
pain progression and occurrence of Serious Reportable Events (SREs) [10]. Similarly results 
from the Phase III COU AA-301 RCT of abiraterone and prednisone versus placebo plus 
prednisone demonstrated better QoL outcomes for the abiraterone group [11-13]. Beneficial 
prostate cancer treatment improves QoL through the reduction in symptoms from the cancer 
itself. 
There is an acknowledgement worldwide that the delivery of health care should embrace 
much more patient participation and involvement as a core element [14]. Pursuant to this, 
ASCO guidelines for survivors of prostate cancer recommend that an individual’s information 
needs at all stages of disease should be assessed, and that patients are provided with or 
referred to sources of appropriate information and support resources [15]. While admirable, 
these goals can be difficult to achieve in under resourced, pressurised hospital clinics. A 
recent survey of UK Health Care Professionals (HCPs) highlighted the challenges of 
providing holistic care for men with mCRPC, especially if they require longer consultations to 
discuss pain management or other supportive care needs [16]. Although limited QoL effects 
are available from patients participating in clinical treatment trials, also there are few real 
world data looking at the impact of approved treatments on men or their information needs. 
Materials and Methods 
Design  
EXTREQOL is a six month longitudinal mixed-methods observational study, using 
questionnaires and interviews to gather views on treatment and care from patients, their 
partners and UK HCPs [16].  We report here the QoL, information needs and pain relief 
results of men commencing different treatments for mCRPC. The interview data will be 
reported separately. 
Patients 
Twenty hospitals in 19 Trusts in England, Scotland and Wales participated and provided 
access to men considered suitable for systemic treatment for mCRPC between July 2016 
Short Title: EXTREQOL study results revision 
4 
 
and July 2017. The study was performed in accordance with the Declaration of Helsinki and 
Ethical approval (16/LO/0403).  Sponsorship and all local NHS R&D permissions were 
obtained for each site.  
Standardised questionnaires 
Standardised PRO measures were used to examine QoL, pain and information needs. 
These were the Functional Assessment of Cancer Therapy – Prostate (FACT-P)[17], the 
Brief Pain Inventory-Short Form (BPI-SF)[18] and the European Organisation for Research & 
Treatment in Cancer (EORTC)- Quality of Life information needs (INFO25)[19]. Patients 
recorded their current mCRPC treatment and other concurrent medication on the QoL record 
and pain relief medication in the section on the BPI-SF at each time point. 
Treatment records 
Information was provided by the clinical team about the treatments discussed at the 
decision-making consultation, if a clinical trial was an option, the site of metastasis, and 
whether or not it was the first presentation of mCRPC. Researchers did not have direct 
access to patient records for any other details such as medical history, co-morbidities, 
performance status or prior treatments. However, life expectancy of >6months was a study 
eligibility criteria.  
Procedures 
Eligible patients were identified and initially approached by a member of the Multidisciplinary 
Team (MDT) treating them who briefly explained the QoL study. Those interested completed 
an expression of interest form providing their contact details. This was faxed to the 
researchers who called patients approximately 24 hours later to answer any questions, and 
confirm whether or not they wanted to participate. Written consent was obtained prior to 
participation. Ethical approval was granted by the London - Surrey Borders Research Ethics 
Committee 16/LO/0403 on the 22nd March 2016. 
Statistical methods 
The proportion of patients who either worsened, remained the same or improved at 3 or 6 
months with respect to baseline, for the FACT-P scales and single items for pain (GP4, P1, 
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P2 and P3) were calculated. Additionally, a longitudinal analysis of the scores was 
undertaken based on linear-mixed effects models for the FACT-P total scores and 
subscales. A Trial Outcome Index (TOI) score was calculated comprising Physical and 
Functional Wellbeing plus the Prostate Concerns Subscale (PCS). The TOI is an efficient 
and common endpoint used in clinical trials, because it is responsive to change in 
physical/functional outcomes. All models included a random intercept to account for the 
correlation among scores collected from the same participant. The models included age, 
partner status, treatment type (chemotherapy, abiraterone, enzalutamide, LHRH agonist 
therapy alone, radium, trials, other or none) and whether this was the first presentation of 
mCRPC at baseline, as explanatory variables. Time varying explanatory variables included, 
period of observation to examine changes over time (3m and 6m) with respect to baseline, 
whether the participant was on treatment and whether they changed treatment during the 
previous period of observation. 
The “worst pain” scores from the BPI-SF were employed for the pain severity analyses. A 
score of ≤4 is considered no or mild pain and a score of >4 is considered moderate or 
severe pain. [18] An additional seven items on the BPI-SF measure pain interference and a 
clinically meaningful change (CMC) in pain severity is defined as a ≥2-point change 
(increase or decrease) from baseline [20]. The proportion of patients whose pain or 
interference either worsened, remained the same or improved at 3 or 6 months with respect 
to baseline were calculated.  
Patients’ information needs produce a Global Score (Max Total is 100) for comparison 
across time and data were summarised using two plots displaying the proportions of “Quite a 
bit/ Very much” answers to questions 31-49 of the INFO25 at baseline and 6 months. A 
linear mixed-effects model for FACT-P was fitted to measure the association between 
information needs being met at baseline and changes in satisfaction and QoL.  
The statistical analyses were undertaken using R [21] and the package lme4 [22]. 
Results 
Recruitment  
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132 patients who were receiving LHRH agonist therapy and diagnosed as mCRPC were 
recruited, and 33/132 participated in the interview sub study (reported separately). Despite 
eligibility criteria of life expectancy >6months, 10 men died, 14 were too ill to continue and 2 
withdrew for other reasons (Figure 1).  84% of men had bone metastases, see Table 1 for 
patient characteristics. 
Sixty-one men remained on the same treatment throughout the study, and 49 changed 
treatment at least once. In the first period (baseline to 3 months) treatments received were 
cabazitaxel (n= 7), docetaxel (n=28), abiraterone (n=20), enzalutamide (n=48), radium 223 
(n=18), dexamethasone (n=6), biclutamide (n=1),  the ProCAID trial (docetaxel + AZD5363 / 
docetaxel alone)  (n=1), the PEACE III trial (radium + enzalutamide / enzalutamide alone) 
(n=1), and the Keynote trial (pembrolizumab + docetaxel + prednisone) (n=1). By TP3 
21/106 (19.8%) were on LHRH agonist therapy alone, having previously received docetaxel 
(n=5), cabazitaxel (n=1), abiraterone (n=2), dexamethasone (n=1), enzalutamide (n=3), and 
Radium -223 (n=7) One patient never started a new treatment and one man remained on 
biclutamide for 6 months. 
Quality of Life  
Table 2 shows the proportion of patients where QoL scores declined, improved or remained 
the same from baseline to 3 and 6 months for the FACT-P total, PCS, TOI and the FACT-G.  
For the group overall there was a significant decline at 6 months on the FACT-P (mean=-
3.89, 95% CI: -6.7 to -1.05, p =0.007); on the FACT-G (mean=-3.45, 95% CI: -5.53 to -1.36, 
p =0.002) and on the TOI (mean=-3.10, 95% CI: -5.34 to -0.83, p =0.007). See Figure 2.  
QoL mean scores were significantly higher (better) in older men on all scales; the mean 
difference in score for a ten-year difference in age between two individuals was 1.8 (95% CI: 
0.26 to 3.35, p=0.022), 7.7 (95% CI: 3.45 to 12.03, p<0.001), 5.91 (95% CI: 2.84 to 8.89, 
p<0.001) and  5.82 (95% CI: 2.48 to 9.16, p=0.001) for PCS, FACT-P, FACT-G & TOI 
respectively. Other studies have shown similar differences with age [23]. 
The linear mixed effects model revealed significant differences at 6 months on the PCS and 
TOI for patients receiving different treatment types. Those who came off a newer treatment 
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and were on LHRH agonist therapy alone had worse scores than those on concomitant 
chemotherapy (PCS mean difference= -4.45, 95% CI: -7.06 to -1.83 p-value=0.001; TOI 
mean difference = -5.62, 95% CI: -10.97 to -0.26, p =0.040). Patients presenting with 
mCRPC for the first time compared with others had higher (better) scores on the TOI (mean 
difference= 6.74, 95% CI:  0.75 to 12.72, p =0.028). On the FACT-P, responses to the single 
item GP4 “I have pain” showed improvements for some from baseline (22% at 3 months; 
29% at 6 months), and also for P1 “I have aches and pains that bother me” (29%; 33% 
respectively).  The majority either remained the same or worsened. 
Pain 
At baseline 23% (29/126) reported no pain, 32% (40) reported mild pain and 45% (57) 
moderate to severe pain on the BPI. Clinically meaningful changes (CMC) in pain severity 
were calculated from baseline across time and patients categorised as those with none or 
little pain (n=69), and those experiencing moderate /severe pain (n=57) at baseline (Tables 
3a and 3b). Table 4 shows the pain relief medication reported at each time point.  Only 15 
men did not require analgesia throughout the study. Sixty percent were taking a combination 
of drugs, for example opioids and paracetamol, but some paracetamol/ibuprofen alone. Five 
had palliative radiotherapy and none received denosumab or zolendronic acid.  
At baseline only 38.5% (22/57) of those with moderate / severe pain experienced >70% pain 
relief from their analgesia.  This dropped to 37.5% (15/40) at 3 months and 36.5% (15/41) at 
6 months.  
Information provision  
The baseline and 6 month plots for INFO25 are shown in Figures 3a and b. There was no 
improvement in information provision for any of the areas. The mean (sd) Global score at 
baseline was 58.49 (18.57), and the mean change at 6m was -1.01 (95% CI: -3.57 to 1.57, 
p=0.44). 
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The linear mixed effects model for FACT-P showed significant between- and within- person 
differences of the global information score on QoL.  Higher Global information scores were 
associated with a better QoL. The mean difference in FACT-P for a ten-point difference in 
information score at baseline between two individuals was 3.53 (95% CI: 1.86 to 5.20, 
p<0.001). The mean change in FACT-P for a ten-point increase in information score for an 
individual was 3.56 (95% CI: 1.60, 5.51, p<0.001). 
 
Discussion  
The findings from the EXTREQOL study showed that overall QoL deteriorated significantly 
across time for this group of men. The majority (84%) had bone metastases, and almost a 
fifth (18%) were lost to follow up due to death or sickness. One of the aims of mCRPC 
treatment is symptom control, particularly pain relief, which in turn should result in improved 
QoL.  
At baseline (57/126) 45% had clinically significant moderate to severe pain which improved 
for 43% by three months. However, over a third with mild or no pain at baseline developed 
pain that interfered with their work, sleep and enjoyment of life.  Our interviews with the men 
and their partners (manuscript submitted) provides some insight into why pain was such a 
problem; this included attributing hip and back pain to old age rather than cancer, and limited 
or no referral to health care professionals for pain management discussions. It is known men 
are more reluctant to seek help with their symptoms and under-report pain [24], which 
makes it challenging for the clinician to deal with it effectively.  
One study showed that pain prevalence and severity were higher in patients with metastatic 
prostate cancer with prior docetaxel exposure and that analgesics were underutilised [25].  
In EXTREQOL less than 25% of men presented with their first progression to mCRPC, and 
we have few data on previous lines of therapy to explore this aspect in more detail. Bone 
pain is a predictive factor for the development of skeletal related events such as a 
pathological fracture, and patients need to be encouraged to report symptoms early to help 
circumvent these potential oncological emergencies such as spinal cord compression [26].  
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Other agents, such as denosumab, have been shown to help relieve bone pain and improve 
QoL in men with mCRPC, but is not routinely available in the UK [27].  
It is common practice to change mCRPC treatment if there are signs of progressive disease, 
and in EXTREQOL 54% of patients had switched to next line therapies. According to a 
recent survey of 118 prostate cancer specialists, most clinicians favour clinical progression 
over prostate-specific antigen or imaging to drive treatment switch decisions [28]. Another 
recent survey of 109 specialists showed that treatment decisions are also influenced by 
whether or not patients live alone. [16] In EXTREQOL treatment type did not appear to 
influence QoL but it was worse for those men where treatment was stopped. The most 
obvious explanation is that these men had relapsed and were experiencing more symptoms 
from their disease. 
Information was lacking on the impact prostate cancer and its treatments might have on the 
patient and his family, how to cope at home and access supportive resources. This was 
made worse by the fact that at six months there was no change in their knowledge. Similar 
gaps in information provision were identified in a series of studies from Canada in men with 
advanced prostate cancer. [29-31]. Of course many clinical factors lead to deterioration in 
health and QoL over time, not only a lack of information or support, but there is strong 
evidence that low literacy and subsequent low levels of information seeking correlates with 
poorer health and worse outcomes [32]. In EXTREQOL; men who had an overall better QoL 
at baseline reported receiving more information about their disease and treatment. These 
findings may reflect better doctor-patient communication, which is shown to have a strong 
influence on QoL [33]. 
The management of mCRPC requires a multidisciplinary team (MDT) approach, with the 
patient receiving information from different specialties, and it is not unusual for patients to 
seek the same piece of information from a series of health professionals. This may be 
because they did not understand it the first time, or want to be sure the message is 
consistent.  Often it is the nurse specialist who covers the largest number of information 
areas including supportive and psychosocial aspects of care [34]. However, in the realm of 
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mCRPC, specialist nurses are rare, and MDTs are dependent on the community teams to 
provide much of the information. UK health care professionals are aware of these 
shortcomings in patient care, especially in understaffed and busy NHS clinics, where many 
men with mCRPC are managed in general urological oncology clinics alongside others with 
a variety of different stages of prostate cancer [16].   
Although our study provides real world QoL data for men receiving mCRPC treatments, 
there are several limitations of the study. These include the relatively small patient sample, 
lack of medical and prostate treatment history and lack of information about treatment 
variation and palliative care team support. These prevent detailed interpretation of the 
results but do not detract from the observation that men with mCRPC outside a trial setting 
have a poor QoL and inadequate pain control. These circumstances make achieving optimal 
quality of life and importantly quality of survival for these patients with more complex needs, 
challenging. Routine use of PROMs in clinics, an increase in advanced nurse specialists, 
early access to the palliative care and/or pain management teams can surely improve the 
lives for these patients and their families. 
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FIGURE LEGENDS 
 
Figure 1: Consort Diagram for EXTREQOL 
 
Figure 2: Estimated mean FACT-P, FACT-G and TOI scores with 95% confidence intervals 
over time using linear-mixed effects models, adjusted for age and whether the patient had a 
partner 
 
Figure 3a: Baseline plot showing very much /quite a bit scores for INFO25 information 
needs 
 
Figure 3b: 6 month plot showing very much /quite a bit scores for INFO25 information 
needs 
 
 
 
 
 
  
Short Title: EXTREQOL study results revision 
15 
 
Table 1: Patient characteristics 
 N=132 
(%) 
Age (years): Mean (SD)   
Min - Max 
73 (7.7) 
52-91 
Presenting with mCRPC for the first time  
Yes 
 
30 (23%) 
Site of metastasis: 
Bone  
Visceral 
Both 
Missing 
 
82 (62%) 
19 (14%) 
29 (22%) 
2 (2%) 
Treatments discussed at baseline for mCRPC:  
abiraterone 16 
abiraterone ; (plus PROMPTS - MRI scanning trial) 1 
abiraterone; docetaxel 1 
abiraterone; enzalutamide 7 
abiraterone; enzalutamide; radium-223 1 
abiraterone; radium-223 1 
biclutamide 1 
biclutamide ; enzalutamide 1 
cabazitaxel 5 
cabazitaxel; olaparib delivered in the TOPARP Trial 1 
cabazitaxel; radium-223, olaparib delivered in the TOPARP Trial 1 
cabazitaxel; radium-223 2 
docetaxel 21 
docetaxel; docetaxel + AZD5363 / docetaxel alone (PROCAID Trial) 4 
docetaxel; enzalutamide 5 
docetaxel; olaparib delivered in the TOPARP Trial 1 
docetaxel: pembrolizumab + chemotherapy (KEYNOTE Trial) 1 
dexamethasone 6 
enzalutamide 35 
enzalutamide; enzalutamide (plus PREMISE observational trial) 3 
enzalutamide; radium + enzalutamide / enzalutamide alone (PEACE III Trial) 2 
enzalutamide ; radium-223 1 
enzalutamide; radium; radium + enzalutamide / enzalutamide alone (PEACE 
III Trial) 
1 
radium-223 10 
radium-223; radium-223 (plus FASTMAN Trial - tissue sampling) 1 
radium-223; radium-223 (plus REASSURE Trial - observational) 2 
missing 1 
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Table 2 shows proportion of patients whose QoL scores declined, improved or remained the 
same from baseline to 3 and 6 months for the FACT – P total, PCS, TOI and the FACT-G 
QoL Measure Decline No change Improve 
 3mths 
N=118 
6mths 
N=106 
3mths 
N=118 
6mths 
N=106 
3mths 
N=118 
6mths 
N=106 
FACT-P 35% (41) 45% (48) 38% (45) 31% (33) 27% (32) 24% (25) 
PCS 37% (44) 47% (50) 22% (26) 24% (25) 41% (48) 29% (31) 
TOI 51% (60) 58% (61) 11% (13) 13% (14) 38% (45) 29% (31) 
FACT-G 34% (40) 40% (42) 42% (49) 41% (42) 25% (29) 20% (21) 
 
 
 
Table 3a Clinically meaningful changes in pain intensity (BPI Q3) for patients who had pain 
intensity (BPI Q3) < 4 at baseline (n=69) and > 4 at baseline (n=57) 
 
  Group 1 
None or little pain at baseline 
(n=69) 
Group 2 
Moderate/severe pain 
at baseline  (n=57) 
  3mths 6mths 3mths 6mths 
Improved 4/63 (6%) 3/58 (5%) 20/47 (43%) 16/40 (40%) 
No change 39/63 (62%) 35/58 (60%) 21/47 (45%) 17/40 (42%) 
Declined 20/63 (32%) 20/58 (34%) 6/47 (13%) 7/40 (18%) 
 
 
Table 3b Clinically meaningful changes in interference score (sum of items from BPI Q9) for 
patients who had pain intensity (BPI Q3) < 4 at baseline (n=69) and those who had pain 
intensity (BPI Q3) > 4 at baseline (n=57)  
 
  Group 1 
None or little pain at baseline 
(n=69) 
Group 2 
Moderate/severe pain 
at baseline  (n=57) 
  3mths 6mths 3mths 6mths 
Improved 21/69 (30%) 17/69 (25%) 33/57 (58%) 37/57 (65%) 
No change 22/69 (32%) 26/69 (38%) 7/57 (12%) 6/57 (11%) 
Declined 26/69 (38%) 26/69 (38%) 17/57 (30%) 14/57 (25%) 
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Table 4: Type of analgesia reported by the patients at each time point 
 
 Baseline 
(n=132) 
3 months 
(n=118) 
6 months 
(n=106) 
no analgesia/not required 39 31 30 
paracetamol/ibuprofen 32 28 19 
codeine +/- paracetamol/ibuprofen 20 15 16 
morphine/ other opioids 27 27 24 
other  e.g. amitriptyline, naproxen 2 5 3 
missing data/ N/A 12 12 14 
radiotherapy (received in combination with 
pain relief medication) 
1 1 3 
combined drug therapy 49/81 (60%) 42/75 (56%) 38/62 (61%) 
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Figure 1: Consort diagram – see separate file 
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Figure 3b:  
 
